Cortical and subcortical patterns of I-123 iodobenzamide SPECT in striatal D2 receptor parkinsonisms

Clinical Nuclear Medicine

Volumn 35, Issue 4, 2010, Pages 228-233

  Pifarre, Paloma ^a   Cuberas, Gemma ^a   Hernández, Jorge ^a   Lorenzo, Carles ^a   Miquel, Francesc ^a   Castell Conesa, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

123 I Iolopride (IBZM); Parkinsonian syndromes

Indexed keywords

BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; FLUOROPROPYL CARBOMETHOXY 3 BETA 4 IODOPHENYLTROPANE; IODOBENZAMIDE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; HUMAN; MALE; PARKINSONISM; PUTAMEN; RELATIVE DENSITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

AGED; AGED, 80 AND OVER; BRAIN; FEMALE; HUMANS; IODOBENZENES; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77950012233     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181d18cb3     Document Type: Article

References (41)

1. LitVan I, Bhatia KP, Burn DJ, et al; Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467-486.
2. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson,s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
3. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci. 1991;18:275-278.
4. Jankovic J. Parkinsonism-plus syndromes. Mov Disord. 1989;4(suppl 1):S95-S119.
5. Cornford ME, Chang L, Millar BL. The neuropathology of parkinsonism: an overview. Brain Cogn. 1995;28:321-341.
6. Siemers E, Reddy V. Profile of patients enrolled in a new movement disorders clinic. Mov Disord. 1991;6:336-341.
7. Poewe W, Wenning G. The differential diagnosis of Parkinson,s disease. Eur J Neurol. 2002;9(suppl 3):23-30.
8. 2 receptor status in patients with Parkinson,s disease, striatonigral degeneration and progressive supranuclear palsy, measured with raclopride and positron emission tomography. Ann Neurol. 1992;31:184-192.
9. 2 receptor is elevated in the striatum of Parkinson,s disease. Mov Disord. 1998;13:788-797.
10. 123I] FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2007;34:502-507.
11. 123I] CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158-1167.
12. Piccini PP. Dopamine transportation: basic aspects and neuroimaging. Mov Disord. 2003;18(suppl 7):S3-S8.
13. Ouchi Y, Kanno T, Okada H, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson,s disease: a double-tracer positron emission tomography study. Ann Neurol. 1999;46:723-731.
14. 123I] CIT pinhole SPECT. Neuroimage. 2002;17:128-141.
15. 2 receptor availability in rats. Neuroimage. 2005;24:822-831.
16. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT SPECT in the diagnostic work up of Parkinsonism. Mov Disord. 2007;22:1229-1238.
17. Poewe W, Scherfler C. Role of DAT SPECT in the diagnostic work up of Parkinsonism. Mov Disord. 2003;18(suppl 7):S16-S21.
18. Lorenzo Bosquet C, Miquel Rodríguez F, Roca Bielsa I, et al. Contribución de la SPET cerebral de transportadores de dopamina en el diagnóstico diferencial de los parkinsonismos [in Spanish] . Med Clin (Barc). 2004;122: 325-328.
19. Leenders KL. Significance of non-presynaptic SPECT tracer methods in Parkinson,s disease. Mov Disord. 2003;18(suppl 7):S39-S42.
20. 2 receptor imaging with a conventional single-head SPET camera. Eur J Nucl Med. 1993;20:680-683.
21. 2) receptor SPECT with 123I iodobenzamide (IBZM) in diagnosis of Parkinson syndrome [in German] . Radiologe. 1995;35:838-843.
22. 2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303-312.
23. 123I] IBZM SPECT and MRI study. Mov Disord. 2002; 17:557-562.
24. Tatsch K, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) receptor ligands. Eur J Nucl Med Mol Imaging. 2002;29:23-29.
25. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163:94-98.
26. LitVan I, Agid Y, Jankovic J, et al. "Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)." Neurology. 1996;46:922-930.
27. Boeve B, Lang AE, LitVan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54(suppl 5):S15-S19.
28. Friston KJ, Holmes AP, Worsley KJ, et al. Statistical parametric maps in functional imaging: a lineal general approach. Hum Brain Mapp. 1995;2: 189-210.
29. Booij J, Speelman JD, Horstink MW, et al. The clinical benefit of imaging striatal dopamine transporters with-123I FP-CIT SPECT in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266-272.
30. Abi Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of ß-CIT. J Nucl Med. 1996;37:1129-1133.
31. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-CIT-FP/SPECT and fluorine-18-FDOPA/ PET. J Nucl Med. 1996;37:1760-1765.
32. 123I] FPCIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson ,s disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140.
33. Strange PG. Dopamine receptors in basal the ganglia: relevance to Parkinson,s disease. Mov Disord. 1993;8:263-270.
34. Wooten GF, Trugman JM. The dopamine motor system. Mov Disord. 1989; 4(suppl 1):S38-S47.
35. Wooten GF. Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson,s disease. Parkinsonism Relat Disord. 2001;8:79-83.
36. Buchert R, Berding G, Wilke F, et al. IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. Eur J Nucl Med Mol Imaging. 2006;33:1073-1083.
37. 3 receptors in early and advanced Parkinson,s disease. Neurology. 2000;54: 1482-1487.
38. 3receptor binding in drug naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry. 2006;60:621-629.
39. 18F] Fallypride. Biol Psychiatry. 2008;63:241-244.
40. Marshall VL, Patterson J, Hadley DM, et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun. 2006;27:933-937.
41. Thobois S, Jahanshahi M, Pinto S, et al. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004;23:1-16.